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ABSTRACT 
 
The Burkholderia genus encompasses many 
Gram-negative bacteria living in the 
rhizosphere. Some Burkholderia species can 
cause life-threatening human infections, 
highlighting the need for clinical interventions 
targeting specific Burkholderia proteins. 
Burkholderia cenocepacia O-linked protein 
glycosylation has been reported, but the 
chemical structure of the O-glycan and the 
machinery required for its biosynthesis are 
unknown and could reveal potential therapeutic 
targets. Here, using bioinformatics approaches, 
gene-knockout mutants, purified recombinant 
proteins, LC-MS–based analyses of O-glycans, 
and NMR-based structural analyses, we 
identified a B. cenocepacia O-glycosylation 
(ogc) gene cluster in necessary for synthesis, 
assembly, and membrane translocation of a 
lipid-linked O-glycan, as well as its structure, 
which consists of a β-Gal-(1,3)-α-GalNAc-
(1,3)-β-GalNAc trisaccharide. We demonstrate 
that the ogc cluster is conserved in the 
Burkholderia genus and confirm the production 
of glycoproteins with similar glycans in the 
Burkholderia species B. thailandensis, B. 
gladioli, and B. pseudomallei. Further, we show 
that absence of protein O-glycosylation 
severely affects bacterial fitness and accelerates 
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bacterial clearance in a Galleria mellonella 
larva infection model. Finally, our experiments 
revealed that patients infected with B. 
cenocepacia, B. multivorans, B. pseudomallei, 
or B. mallei develop O-glycan–specific 
antibodies. Together, these results highlight the 
importance of general protein O-glycosylation 
in the biology of the Burkholderia genus and its 
potential as a target for inhibition or 
immunotherapy approaches to control 
Burkholderia infections. 
_____________________________________ 
 
 The Burkholderia genus encompasses 
widespread environmental Gram-negative 
bacteria adapted to survive in the rhizosphere 
and fresh water (1,2). Some Burkholderia 
species including those in the B. cepacia 
complex, B. mallei, and B. pseudomallei cause 
life-threatening infections in humans. The B. 
cepacia complex encompasses over 18 closely 
related species typically infecting patients with 
cystic fibrosis; some of these species, 
especially B. cenocepacia, cause the fatal 
cepacia syndrome (3). B. mallei and B. 
pseudomallei are potential biological warfare 
agents (4), which cause glanders and 
melioidosis, respectively. B. mallei typically 
infects horses, donkeys and mules, which are 
the primary reservoir of this mammalian-
adapted pathogen that evolved from the 
environmental pathogen B. pseudomallei 
through gene loss (5). Glanders is characterized 
by pneumonia, often with systemic sepsis, or by 
skin and lymph node disease (Farcy). B. 
pseudomallei is endemic to southeast Asia and 
northern Australia and is being increasingly 
recognized in the tropics globally, including 
Africa and the Americas (6-8). Melioidosis can 
be acquired by inhalation or through skin 
abrasions or ingestion, causing a wide spectrum 
of symptoms including pneumonia and rapidly 
progressive systemic sepsis (7). B. 
pseudomallei can also remain latent and 
asymptomatic, with subsequent activation and 
presentation as melioidosis many years after 
initial exposure (9). Antibiotic treatment of 
Burkholderia-related infections is difficult due 
the high-level intrinsic multidrug resistance of 
these bacteria (10), and there are no clinically 
approved vaccines for either melioidosis or 
glanders prevention in humans or animals (11). 
 Protein glycosylation is a post-
translational modification that modulates 
protein physicochemical properties and 
functions, and is common in bacteria (12-14). 
Glycans may be attached to the amide nitrogen 
of asparagine residues of a polypeptide (N-
glycosylation) or to hydroxyl oxygen of serine 
or threonine residues (O-glycosylation) (15). In 
other cases, α-mannopyranose can be linked to 
tryptophan via a carbon-carbon link (C-
mannosylation) (16) and glycans can also be 
attached to the sulfur of cysteine (S-linked 
glycosylation) (17). The N-linked general 
protein glycosylation pathway in bacteria was 
first elucidated in Campylobacter jejuni 
(18,19). This system includes the 
oligosaccharyltransferase (OTase) PglB (20), 
which is homologous to the eukaryotic Stt3, the 
catalytic subunit of the OTase complex 
responsible for N-glycosylation in the lumen of 
the endoplasmic reticulum. 
 O-glycosylation systems have also been 
noted in many different bacteria (12-15). The 
O-glycosylation of at least 23 proteins with an 
uncharacterized predicted trisaccharide glycan, 
mediated by the OTase PglL, was previously 
identified in B. cenocepacia (21). However, the 
genes and gene products for the B. cenocepacia 
glycosylation machinery and the chemical 
structure of the glycan moiety were not 
elucidated. In this study, we report the 
identification of the Burkholderia O-
glycosylation (ogc) cluster, which includes 
genes in chromosome 1 of B. cenocepacia 
(BCAL3114 to BCAL3118) encoding the 
enzymes required for the stepwise assembly of 
the lipid-linked O-glycan in the cytoplasm and 
its flipping across the inner membrane. We also 
discovered these genes are present in all species 
of Burkholderia and confirm biochemically the 
presence of O-linked proteins in several species 
of Burkholderia, suggesting protein O-
glycosylation is a conserved feature of this 
genus. To elucidate the biosynthesis of the O-
linked glycan, we generated knockout mutants 
in the ogc genes characterizing their effect on 
glycosylation and assessing the function of the 
epimerase within this cluster. From these 
studies we have confirmed the predicted role of 
the ogc genes and also established the structure 
of the trisaccharide glycan. We also show that 
O-glycosylation is required for bacterial fitness 
in vitro and survival in a larvae infection model. 
Lastly, we demonstrate that individuals 
previously infected with B. cenocepacia, B. 
multivorans, B. pseudomallei and B. mallei 
develop anti-O-glycan serum antibodies, 
suggesting Burkholderia glycoproteins display 
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a common epitope perceived by the human 
immune system.  
 
RESULTS 
 A predicted B. cenocepacia O-
glycosylation gene cluster is conserved in the 
Burkholderia genus. Previous work identified 
PglL (BCAL0960) as the OTase catalyzing the 
addition of an uncharacterized trisaccharide O-
glycan to least 23 B. cenocepacia proteins (21). 
In OTase-dependent glycosylation pathways, 
the lipid-linked glycan precursor is assembled 
on the cytoplasmic side of the membrane, 
translocated across the membrane, and then 
transferred onto acceptor proteins at the 
periplasmic side (22). We therefore 
hypothesized that at least four genes encoding 
a phosphoglycosyl transferase (initiating 
enzyme that mediates the synthesis of a lipid-
linked sugar) (23,24), two additional 
glycosyltransferases, and a flippase protein 
would be required for the synthesis and 
translocation of a B. cenocepacia lipid-linked 
trisaccharide glycan (22,24). The chromosome 
1 of B. cenocepacia has a putative five-gene 
operon flanked by the O-antigen synthesis 
cluster and lipid A-core biosynthesis genes (25) 
(Fig. 1A), which could be involved in protein 
glycosylation. These genes were previously 
annotated, according to their predicted 
functions, as wecA (BCAL3118, 
phosphoglycosyl transferase), galE 
(BCAL3117, UDP-glucose epimerase), wbxA 
and wbxB (BCAL3116 and BCAL3115, 
glycosyltransferases, GT2 family forming b-
glyosidic bonds and GT4 family forming a-
glyosidic bonds, respectively) and wzx 
(BCAL3114, flippase) (25). This putative 
operon was herein renamed ogc (for O-
glycosylation) (see below). The last ogc gene, 
BCAL3118, which encodes a predicted UDP-
N-acetylhexosamine-1-P transferase 
homologous to WecA-like initiating enzymes 
for O-antigen synthesis, was renamed ogcI (for 
initiating transferase). The immediately 
upstream gene, BCAL3117, encodes a protein 
similar to UDP-glucose-4-epimerases of the 
NAD-dependent epimerase/dehydratase 
family, and it was renamed ogcE. The two 
predicted glycosyltransferase encoding genes, 
BCAL3115 and BCAL3116, were renamed 
ogcA and ogcB, respectively. BCAL3114, 
renamed ogcX, encodes a predicted flippase 
protein belonging to the Wzx-like 
polysaccharide transporter family. Therefore, 
the ogc cluster encodes proteins whose 
predicted functions fit well with the required 
enzymatic activities to assemble the lipid-
linked trisaccharide glycan for protein 
glycosylation, according to the model depicted 
in Fig. 1B. 
 Using the SyntTax web server (26) and 
the Burkholderia genome database (27), we 
discovered the ogc cluster is conserved in the 
majority of Burkholderia and 
Paraburkholderia species whose genomes 
have been sequenced (Fig. 1C). Most species 
retain the five-gene cluster with the genes 
arranged as in B. cenocepacia. In a reduced 
number of species, ogcXABE remain together 
while ogcI appears as a single monocistronic 
gene separated from the cluster by a variable 
number of genes depending on the species 
examined (Fig. 1C). In P. rhizoxinica, ogcB is 
present as a monocistronic gene while the rest 
of the genes, ogcXAEI, form a putative operon 
(Fig. 1C). Therefore, the ogc cluster appears to 
be a highly conserved loci encoding the 
minimal set of gene products to produce the 
trisaccharide O-linked glycan observed in B. 
cenocepacia.  
 A deletion mutant of the ogc cluster 
cannot glycosylate proteins. To validate the 
ogc cluster's role in protein glycosylation, we 
constructed an unmarked deletion mutant 
(∆ogc) in the B. cenocepacia strain K56-2, and 
a ∆pglL mutant as a control. We also generated 
the individual unmarked, non-polar deletion 
mutants ∆ogcX, ∆ogcI, ∆ogcAB, and ∆ogcE. In 
parallel, we constructed recombinant plasmids 
expressing His-tagged fusion forms of 
BCAL2640 and the DsbA1 protein from 
Neisseria meningitidis. BCAL2640 is a native 
glycosylated protein in B. cenocepacia, while 
the heterologously expressed DsbA1 is 
glycosylated by PglL (21) and also by several 
different OTases (28). Expression of 
BCAL2640 and DsbA1 was examined in the 
K56-2 parental strain and its isogenic ∆ogc and 
∆pglL mutants. The purified BCAL2640 
polypeptide obtained from ∆ogc and ∆pglL had 
increased relative mobility compared to that 
obtained from the parental strain, suggesting 
loss of glycosylation (Fig. 1D, left panel). 
Similarly, examination of DsbA1 mobility by 
immunoblot with anti-His tag antibodies also 
revealed DsbA1 polypeptides of lower apparent 
mass in samples purified from ∆ogc and ∆pglL, 
as well as from ∆ogcX, ∆ogcI, ∆ogcAB, and 
  4 
∆ogcE mutants (Fig. 1D, right panel). 
Conversely, no difference in protein mobility 
was observed in DsbA1 expressed in an O-
antigen synthesis deletion mutant 
ΔBCAL3119-BCAL3131, ruling out any 
contribution of the O antigen genes to protein 
glycosylation (Fig 1D, right panel).  
 To directly monitor the glycosylation 
status of purified BCAL2640 expressed in 
strains K56-2, ∆ogc and ∆pglL, the purified 
protein was digested with trypsin, and analyzed 
by liquid chromatography–mass spectrometry 
(LC-MS). The trypsin-derived BCAL2640 
peptide 
152YAPPPAAVPVAATSGAQGGAAAAAAP
AGTKPANAPR187, previously shown to be 
glycosylated (at the underlined serine residue) 
(21), was readily observable. Tandem mass 
spectrometry (MS/MS) and fragmentation by 
collision-induced dissociation (CID) confirms 
the peptide is modified with at least two glycans 
corresponding to HexNAc-HexNAc-262 (Fig. 
2A) and HexNAc-HexNAc-Hex (Fig. 2B), 
while higher-energy collisional dissociation 
(HCD) fragmentation confirmed the peptide 
sequence (Fig. 2C). The glycosylated form of 
this peptide was 15-fold more abundant than 
the unglycosylated form, indicating the 
majority of BCAL2640 was glycosylated (Fig. 
2D). In contrast, this glycopeptide was absent 
in the purified protein obtained from ΔpglL or 
Δogc mutants (Fig. 2e and f). Therefore, 
deletion of the ogc cluster causes the same 
defect in protein glycosylation as the loss of the 
OTase PglL, demonstrating it contains the 
genes encoding functions for the synthesis and 
assembly of the protein glycan.   
 Structural characterization of the O-
glycan. To determine the structure of the B. 
cenocepacia O-glycan, glycopeptides modified 
with the trisaccharide were generated from 
glycosylated DsbA1 by digestion with 
proteinase K and enriched by size exclusion 
chromatography. This glycopeptide fraction 
was identified by nuclear magnetic resonance 
(NMR) spectroscopy analysis by both homo- 
and heteronuclear two-dimensional NMR 
experiments (Fig. 3A and Table S1). The 
heteronuclear single quantum coherence 
(HSQC) spectrum (Fig. 3B) showed three main 
anomeric signals with 1H/13C values at 
5.07/94.5, 4.63/101.7, and 4.45/106.3 ppm 
(Fig. 3A), each labeled with a capital letter. For 
the A spin system, total correlation 
spectroscopy (TOCSY) displayed three 
correlations that connected H-1 up to H-4 (Fig. 
3c and Table S1). The attribution of these 
densities to the right proton in the sequence was 
inferred by analyzing the homonuclear 
correlation (COSY) spectrum, while the 
position of H-5 was identified by the H-4/H-5 
correlation in the transverse rotating-frame 
Overhauser enhancement (T-ROESY) 
spectrum, which in turn defined the position of 
the two H-6 protons at 3.76 ppm. These results, 
together with those derived from the HSQC 
spectrum (Fig. 3B) and the H-2/C-2 values 
(4.38/51.0 ppm) along with the presence of an 
acetyl group in the proton spectrum, indicated 
that A was N-acetylgalactosamine. The 3JH1,H2 
value (3.3 Hz) pointed to a α-configuration for 
the anomeric centre. In addition, the downfield 
displacement of C-3 (79.1 ppm) with respect to 
the standard value (72.3 ppm) (29) indicated a 
substitution at this position. 
 For B and C residues, their 3JH1,H2 values 
(8.4 and 8.0 Hz, respectively) disclosed their β 
configuration at the anomeric center. Using the 
same approach as described for residue A, 
residue B was identified as N-
acetylgalactosamine (H-2/C-2 values at 
4.11/52.0 ppm) and residue C as galactose 
(H2/C-2 values at 3.51/71.6 ppm). The 
comparison of the carbon chemical shifts of 
these two residues with those taken as reference 
(29) showed that C-3 of B (75.8 ppm) and C-6 
of C (64.4 ppm) were shifted downfield with 
respect to the standard values (72.3 and 62.0 
ppm, respectively), suggesting the presence of 
a substitution at these positions. The sequence 
of the three units was inferred by NOE contacts 
found in the T-ROESY spectrum among H-1 of 
A and both H-3 and H-4 of B, and H-1 of C 
with H-3 of A (Fig. 3c). Therefore, combining 
data from the nuclear Overhauser effects with 
the 13C chemical shift displacement observed 
allowed us to build the sequence C-(1®3)-A-
(1®3)-B. Importantly, H-1 of B did not 
correlate with any sugar-related signal, but only 
with protons related to the peptide moiety, for 
which we conclude the glycan structure is: β-
Gal-(1®3)-α-GalNAc-(1®3)-β-GalNAc-
(1®) directly linked to the protein (Fig. 3B). 
The T-ROESY spectrum did not contain cross-
peaks connecting to any of the two H-6 of C to 
the substituent at O-6, but the type of chemical 
displacement of C-6 and C-5, along with the 1H 
chemical shift of both H-6s, suggested the 
presence of an acyl substituent that was 
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consistent with a succinylated hexose residue, 
observed as a mass of 262 Da by MS analysis, 
but remains to be structurally identified by 
NMR.  
 Dual role of OgcE in protein 
glycosylation and O-antigen synthesis. The 
predicted OgcE epimerase (Fig. 1A) could be 
required for the synthesis of UDP-GalNAc, 
UDP-Gal or both, which are the expected 
precursors for the assembly of the trisaccharide 
glycan. However, the O antigen in B. 
cenocepacia K56-2 is composed of a GalNAc-
GalNAc-Rha repeating unit (25), suggesting 
UDP-GalNAc is a common precursor for both 
O-antigen and protein glycan trisaccharide 
synthesis in this strain. To determine if OgcE is 
also required for O-antigen synthesis, we 
examined the lipopolysaccharide (LPS) profile 
of K56-2, ∆pglL, ∆ogc, and various deletion 
mutants in ogc genes. Only the ∆ogc and ∆ogcE 
mutants produced truncated O antigen, as 
indicated by a strong band migrating above the 
band corresponding to lipid A-core and the loss 
of bands corresponding to polymeric O antigen 
(Fig. 4A). The O antigen in B. cenocepacia 
K56-2 is synthesized via the ABC export 
pathway (25,30). This requires an adaptor 
sugar, bound to undecaprenyl-PP, to which the 
repeating O-antigen units are attached, and this 
sugar in K56-2 is QuiNAc (31). Therefore, the 
truncated O-antigen band, in the absence of 
UDP-GalNAc due to the loss of ogcE (Fig. 4A, 
asterisk), was interpreted as lipid A-core plus 
Rha-QuiNAc disaccharide. We have previously 
shown that a similar band appears in a GalNAc 
transferase mutant (25). Complementation of 
∆ogc with a plasmid expressing OgcE restored 
full O-antigen synthesis (Fig. 4A), but did not 
restore protein glycosylation (Fig. 4B). 
Therefore, OgcE (BCAL3117) participates in 
both the synthesis of O antigen and the protein 
glycan (Fig. 4A and B), while the remaining 
ogc genes are not involved in O-antigen 
synthesis.  
 OgcE is a UDP-Glc and UDP-GlcNAc 
epimerase. To elucidate the biochemical 
function of OgcE, we examined its enzymatic 
activity by capillary electrophoresis. Purified 
OgcE showed C4 epimerase activity on UDP-
Gal and UDP-Glc (Fig. 5A and C), reaching a 
final equilibrium of 79 % UDP-Glc and 21% 
UDP-Gal, irrespective of the starting substrate. 
OgcE also had C4 epimerase activity on UDP-
GalNAc and UDP-GlcNAc (Fig 5B and D), 
reaching a final equilibrium of 68 % UDP-
GlcNAc and 32 % UDP-GalNAc with either 
substrate. Identical results were obtained with 
both NAD+ (Fig. 5A and B) and NADP+ (Fig. 
5C and D), suggesting the enzyme does not use 
any of these exogenously supplied cofactors. 
This conclusion is further supported by the 
unaltered amount of input cofactor after 
catalysis, the lack of release of reduced NADP+, 
and because catalysis can also occur in the 
absence of any cofactor (Fig. S1, top two 
traces). A small amount of NADH was 
observed in all enzyme-containing reactions 
irrespective of the type of cofactor exogenously 
added, but no NADPH was released. Since the 
NADH appearance occurs irrespective of the 
type of added substrate or exogenous cofactor 
and is not proportional to the amount of 
catalysis, we surmised that the detected NADH 
was released by the enzyme. Indeed, release of 
NADH was also observed in control reactions 
performed without substrate (Fig. S1, bottom 
trace). This suggests the OgcE preferentially 
binds NAD+ over NAPH during overexpression 
in E. coli and explains why the bound cofactor 
alleviates the need for any exogenous cofactor. 
The release may occur due to progressive 
unfolding of the enzyme during lengthy 
incubations at 37 °C. To assess which type of 
substrate is most efficiently catalyzed, reactions 
were performed with serial dilutions of enzyme 
on UDP-Gal and UDP-GalNAc. These 
substrates were selected over UDP-Glc and 
UDP-GlcNAc since as high as 79 and 67% 
catalysis can be observed with UDP-Gal and 
UDP-GalNAc (versus only around 25-30% 
starting from their glucose counterparts). 
Enhanced catalysis of UDP-Gal versus UDP-
GalNAc was observed at all enzyme dilutions 
and all time points tested (Fig. S2 and S3). 
Therefore, we conclude OgcE is an epimerase 
with dual specificity for the interconversion of 
UDP-Gal/UDP-Glc and UDP-GlcNAc/UDP-
GalNAc, with slightly higher efficiency for 
non-acetylated substrates. 
 Predicted function of the remaining 
genes in the ogc cluster. To gain clues on the 
function of the remaining ogc genes we 
investigated the glycosylation status of the 
DsbA1 derived peptide 
23VQTSVPADSAPAASAAAAPAGLVEGQN
YTVLANPIPQQQAGK64 in the various ogc 
gene deletion mutants. MS spectra of the 
DsbA1 derived peptide in K56-2, ΔpglL, ∆ogc, 
∆ogcX, ∆ogcI, ∆ogcAB and ∆ogcE are shown 
in Fig. S4. Using HCD fragmentation, four 
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glycoforms of this peptide were identified, with 
all glycopeptides showing nearly identical 
peptide fragmentation maps (Fig. 6A). The 
glycan attached to the four glycoforms 
corresponded to: HexNAc-HexNAc-Hex 
(Glycan A), HexNAc-HexNAc-262 (Glycan 
B), QuiNAc-Rha, and a single HexNAc (Fig. 
6B). The area under the curve of the extracted 
ion chromatograms for all observed glycoforms 
of the peptide enabled us to semi-quantitatively 
compared each state (Fig. 6C and Table S2). 
The results show that glycoforms A and B were 
present in K56-2 with relative abundances of 
44% and 52%, respectively, while the reminder 
4% of the peptide was unmodified. In contrast, 
100% and 84% of unmodified peptide was 
found in preparations obtained from ∆pglL and 
∆ogc, respectively. The peak in ∆ogc with a 
relative abundance of 16% corresponded to a 
peptide modified by a glycan with the predicted 
mass of a QuiNAc-Rha disaccharide. As shown 
previously (Fig. 4A), deletion of the ogc cluster 
results in a truncated O antigen containing a 
terminal QuiNAc-Rha attached to the lipid A 
core (Fig. 4A, asterisk). Therefore, we 
interpreted this result as due to the 
incorporation of the QuiNAc-Rha disaccharide, 
which is assembled as Und-PP-QuiNAc-Rha 
by the O antigen synthesis machinery and likely 
transferred to the target protein by PglL. In 
contrast, the ∆ogcI mutant lacked glycosylated 
peptides, as the glycan assembly is blocked at 
its initiation step (Fig. 6C, Table S2 and Fig. 
S4). Both ∆ogcX and ∆ogcAB showed 
predominantly unmodified peptide with 90% 
and 65 % relative abundance, respectively. The 
remainder glycosylated peptide in these 2 
mutants corresponded to an HexNAc glycan 
form (Fig. 6C, Table S2 and Fig. S4). The low 
abundance of a modified peptide with a single 
HexNAc in ∆ogcX, (9%) suggest the possibility 
that another flippase in the B. cenocepacia 
genome could mediate in part the membrane 
translocation of Und-PP-GalNAc (32). A single 
∆ogcB mutant also resulted in the production of 
HexNAc decorated glycoproteins as in 
∆ogcAB, supporting the assignment of OgcB as 
the enzyme responsible for the addition of the 
second GalNAc (Figure S5). Multiple attempts 
to delete ogcA were unsuccessful. It is possible 
that the absence of this gene may be deleterious 
for bacterial cell viability due to the 
accumulation of an Und-PP-linked GalNAc 
disaccharide that cannot be processed further, 
suggesting that OgcA is responsible for the 
addition of the terminal Gal and explaining why 
∆ogc, ∆ogcAB, and ∆ogcB are well tolerated. 
 O-glycosylation is common in other 
Burkholderia species. The gene-by-gene 
conservation of the ogc cluster in the 
Burkholderia genus (Fig. 1C) suggests that 
protein glycosylation with β-Gal-(1®3)-α-
GalNAc-(1®3)-β-GalNAc-(1® is widespread 
within Burkholderia species. We tested this 
idea in two ways. First, we showed that 
glycosylated proteins in lysates from B. 
cenocepacia, B. thailandensis and two different 
strains of B. gladioli can be detected using the 
peanut agglutinin (Fig. S6). This lectin has 
specificity for Gal-β(1-3)-GalNAc terminal 
disaccharides. Second, bacterial glycopeptides 
were investigated by LC-MS in isolates 
representing several different Burkholderia 
species. Glycopeptides derived from five 
proteins were readily detectible from whole 
proteome samples of B. thailandensis E264 
(Supplementary Data S1), such as the peptide 
159PAAASGAPAPAASGAAAH176 of 
BTH_I3002ABC, which corresponds to the 
periplasmic substrate-binding protein of an 
ABC transporter (Fig. 7) and is modified with 
the expected HexNAc-HexNAc-Hex. As with 
B. cenocepacia glycopeptides (21), we also 
noted the presence of HexNAc-HexNAc-262 
and an additional modified glycan 
corresponding to HexNAc-HexNAc-362 in B. 
thailandensis (Supplementary Data S1). 
Examination of whole cell lysates from two 
clinical isolates of B. gladioli revealed at least 
14 glycosylated proteins (Supplementary Data 
S2 and S3). The analysis of one of the 
glycosylated peptides, 
594AAHPGDIASEAAATGQPR611, of the B. 
gladioli bifunctional uroporphyrinogen-III 
synthetase/uroporphyrin-III is shown in Fig. 7. 
Analysis of eight clinical isolates of B. 
pseudomallei revealed three modified proteins, 
one of which was identified across all eight 
clinical isolates and corresponded to the known 
virulence factor Ecotin (33) (Fig. 7 and 
Supplementary Data S4). As in the other cases, 
the B. pseudomallei glycopeptides were also 
modified with either HexNAc-HexNAc-Hex or 
HexNAc-HexNAc-262. Collectively, our 
results demonstrate that protein glycosylation 
occurs in Burkholderia species outside B. 
cenocepacia and that the addition of the 
HexNAc-HexNAc-Hex glycan appears to be an 
invariant feature across members of this genus. 
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 Loss of O-glycosylation is associated to 
growth defects under many different carbon 
sources as well as oxidative and osmotic 
stress. The conservation of the O-glycosylation 
pathway in the Burkholderia genus suggested it 
might be necessary for bacterial cell 
homeostasis. Therefore, we performed a global 
comparative analysis of carbon sources utilized 
by the K56-2 parental strain and ∆pglL using 
phenotypic microarrays (Biolog). The results 
show that ∆pglL utilized exogenous carbon 
sources less effectively than K56-2, especially 
sugar alcohols such as xylitol, monosaccharides 
(L-arabinose and D-mannose), deoxysugars (L-
fucose and 2-deoxy-ribose), and various amino 
acids (D-alanine, L-alanine, D-serine, L-
arginine, L-lysine and L-ornithine) (Fig. 8A and 
Supplementary Data S5). Also, ∆pglL could not 
utilize putrescine, which is produced from L-
ornithine by ornithine decarboxylase 
(BCAL2641 and BCAM1111) or from L-
arginine by arginine decarboxylase 
(BCAM1112) (34). Further, ∆pglL grew poorly 
in media with tweens, formic acid, butyric acid, 
D-glucosaminic acid and D-galacturonic acid. A 
subset of significant phenotypic microarray 
differences resulting in growth defects relative 
to the parental strain were independently 
validated (Fig. 8B). We also examined the 
sensitivity of ∆pglL towards oxidative stress 
under a range of H2O2 concentrations. The 
results showed that the mutant has higher 
sensitivity towards H2O2 than K56-2 (Fig. 
S7A). Because in long-term exposure 
experiments bacteria could adapt to H2O2 stress 
and since H2O2 is short-lived, we also 
performed a challenge experiment. In this case, 
bacteria were challenged with either 300 μM or 
1 mM of H2O2 with bacterial inoculum of OD600 
of 0.01 and 0.1 respectively for 1 h at 37°C. In 
both conditions, we found more than a 30% 
reduction in ∆pglL survival relative to K56-2 
(Fig. 7SB). The ∆pglL mutant was also more 
susceptible to osmotic stress induced by high 
salt (4% NaCl) than K56-2 parental strain (Fig. 
S7C). We also noted that the ∆pglL mutant was 
more proteolytically active than the parental 
strain (Fig. 8C and D), a phenotype that was 
complemented by a plasmid carrying a 
functional pglL gene. Collectively, the results 
indicate that in the absence of protein 
glycosylation B. cenocepacia displays a global 
defect in utilization of multiple carbon sources, 
increased proteolytic activity, and reduced 
tolerance to stress conditions. We therefore 
conclude that the general protein O-
glycosylation pathway may be important for the 
metabolic fitness of Burkholderia. 
 Loss of protein glycosylation reduces 
bacterial growth in the Galleria mellonella 
infection model and results in a rapid 
activation of the larval antimicrobial 
response. ∆pglL was previously reported to be 
avirulent in the wax moth G. mellonella and the 
duckweed Lemna minor, which are widely used 
insect and plant infection models, respectively, 
based on end-point experiments (21). However, 
the mechanisms for the reduced virulence was 
not investigated. First, we compared the 
virulence of the O-glycan defective mutants 
and the bacterial loads recovered from the G. 
mellonella haemolymph over 72-h infections. 
Under our experimental conditions, the parental 
K56-2 strain caused death of all larvae at 48 h 
postinfection (Fig. 9A), while larvae infected 
with ∆pglL and ∆ogc had survival rates of 80% 
and 98%, respectively. We attributed the 
reduced virulence of ∆ogc (compared to ∆pglL) 
to the cumulative effect caused by the 
simultaneous loss of protein glycosylation and 
O antigen synthesis due to absence of ogcE in 
∆ogc (Fig. 4). Consistent with this, a strain in 
which ∆ogc was complemented by OgcE 
retained the same virulence level as ∆pglL at 48 
and 72 h postinfection (Fig. 9A). Second, we 
examined whether decreased virulence is 
associated with poor growth of the O-
glycosylation defective mutants in the infected 
larvae. Analysis of bacterial growth in larval 
haemolymph showed a 5-log increase in K56-2 
(relative to the initial inoculum) at 48 h 
postinfection (p < 0.01; Fig. 9B). In contrast, 
∆pglL and ∆ogc bacteria only showed 2-log 
CFU increase at 48 h and ∆ogc demonstrated 
poorer growth overall compared to ∆pglL 
despite the differences were not statistically 
significant.   
 Third, we determined whether the 
significantly reduced virulence and in larvae 
growth of the O-glycosylation defective 
mutants correlated with rapid killing mediated 
by the G. mellonella’s innate immune system. 
For this, we determined the expression pattern 
of innate immune genes in the infected larvae 
by RT-qPCR analysis. The results showed that 
the levels of cecropin and galliomycin 
transcripts were 6 to 11-, and 4-fold higher, 
respectively, in larvae infected with ∆pglL and 
∆ogc than in those infected with K56-2 at 8 h 
postinfection (Fig. 9C), while the levels of the 
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galleriomycin transcripts did not differ at this 
time. By 18 h postinfection, the levels of 
cecropin and galleriomycin transcripts 
increased dramatically in larvae infected with 
the three strains, but the increased expression 
was more significant in larvae infected with 
K56-2. Lower levels of cecropin gene 
expression in Galleria infected with ∆ogc  at 18 
h could be related to the rapid death of bacterial 
cells.  For galliomycin, the transcript levels did 
not increase much, although they were still 
significantly higher in larvae infected with 
∆pglL and ∆ogc than in those infected with 
K56-2 (Fig. 9C). As infection in K56-2 was 
accompanied by increased pigmentation, we 
inferred the level of melanin formation by 
measuring the expression of the peptidoglycan 
recognition protein B (PGRP) gene. PGRP is a 
microbial pattern recognition molecule that 
recognizes bacterial cell fragments and 
mediates host responses towards bacterial 
infections through activation of 
prophenoloxidase cascade, responsible for 
melanization of pathogens and dead tissues, 
activation of Tol1 receptor and phagocytosis 
induction (35). We found that the level of 
PGRP gene transcription was similar for larvae 
infected with the three strains at 8 h 
postinfection, but at 18 h the increase in PGRP 
gene expression was significantly higher in 
larvae infected with the parental strain than in 
those infected with the O-glycosylation 
mutants (Fig. 9C). In contrast, transcript levels 
of the inducible metallo-protease inhibitor 
gene, which encodes a host inhibitor of 
bacterial proteases (36), remained similar but 
significantly higher in larvae infected with both 
K56-2 and ∆pglL than with ∆ogc. The 
expression of the gene encoding the cell wall 
degrading enzyme lysozyme (37) remained the 
similar in larvae infected with K56-2 or both O-
glycosylation defective mutants, albeit their 
levels dramatically increased from 8 to 18 h 
postinfection. Collectively, these findings 
support the notion that the G. mellonella innate 
immune system responds early to infection by 
O-glycosylation defective bacteria, which 
compounded by reduced bacterial growth and 
reduced resistance to oxidative stress, could 
result in rapid and early killing of the mutant 
bacteria.  
 Burkholderia infected patients develop 
serum antibodies against the Burkholderia 
O-glycan. Given the previous results and the 
conservation of the O-glycosylation pathway in 
Burkholderia species, we examined if infected 
patients develop antibodies specifically 
recognizing Burkholderia O-glycoproteins. For 
these experiments, we deliberately chose the N. 
meningitidis DsbA1 as an heterologous 
glycosylation target expressed in Burkholderia 
to screen human sera because the assay was 
designed to reveal antibodies recognizing the 
Burkholderia glycan independently of the 
nature of the target protein. The N. meningitidis 
DsbA1 contains the sequence PAAASAAA 
with an invariable serine for O-glycosylation, 
which is similar to the glycosylation motif for 
the Burkholderia proteins. Convalescent sera 
collected from 16 patients infected with B. 
cenocepacia, 14 patients infected with B. 
multivorans, 20 patients infected with B. 
pseudomallei, and one patient infected with B. 
mallei were investigated for the presence of 
antibodies against purified glycosylated DsbA1 
expressed in the K56-2 strain. Fourteen of the 
16 samples isolated from B. cenocepacia 
infected patients contained antibodies against 
glycosylated DsbA1 protein, while only two 
serum samples reacted with non-glycosylated 
DsbA1 (Fig 10A, thick arrows). For B. 
multivorans infected patients, 13 of the 14 
serum samples tested gave positive reaction 
with glycosylated DsbA1 (Fig. 10B). Also, 16 
of the 20 samples tested for patients with B. 
pseudomallei reacted with glycosylated DsbA1 
and not with the non-glycosylated version (Fig. 
10B). This amounts to 86% of the tested serum 
samples giving positive reaction in the ELISA 
assay with glycosylated DsbA1. To confirm 
that the serum samples contained Burkholderia 
O-glycan specific antibodies, positive samples 
were adsorbed against glycosylated DsbA1 by 
serial passage on microtiter plates containing 
bound glycosylated protein and the adsorbed 
serum samples were then retested by ELISA. 
The results showed that all the originally 
positive samples became negative after 
adsorption (Fig. 10B). Together, the results 
reveal that the majority of the convalescent 
serum samples investigated had antibodies 
toward the Burkholderia glycan, indicating that 
either the glycan itself or the glycosylated 
proteins are antigens recognized upon human 
infection with Burkholderia species. Also, the 
results indicate that the antibodies recognize the 
glycoprotein made in B. cenocepacia 
irrespective of the type of infection cause, 
providing additional evidence that the infecting 
bacteria produce the same O-glycan. 
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DISCUSSION 
 In this study, we have uncovered the gene 
cluster encoding the enzymes responsible for 
the synthesis and assembly of the lipid-linked 
glycan precursor for the general protein O-
glycosylation pathway in B. cenocepacia and 
also elucidated the glycan structure as the 
trisaccharide b-Gal-(1-3)-a-GalNAc-(1-3)-b-
GalNAc-peptide. As previously reported (21), 
we found two forms of the O-glycan, one of 
which corresponds to a modified trisaccharide. 
Our data suggest that the trisaccharide core 
moiety of both glycans derives from the ogc 
pathway, while the modification likely involves 
non-stoichiometric succinylation at the 
terminal Gal residue. Succinylation appears as 
a variable modification in glycans from 
Rhizobium meliloti (38) and several other 
Proteobacteria (39). Further studies are 
required to elucidate the structure of the 
modified glycan and identify the gene encoding 
the modifying enzyme.  
 Finding the ogc genes allowed us to 
predict gene functions, most of which were 
validated by single or double deletion 
mutagenesis followed by LC-MS analyses of 
the resulting glycopeptides. Thus, the OgcI 
protein was assigned as a member of the WecA 
family of phosphoglycosyltransferases, which 
catalyze the formation of undecaprenyl-
diphosphate sugars typically utilizing UDP-
GlcNAc or UDP-GalNAc as nucleotide sugar 
substrates (24). Our results support the 
assignment of OgcB as the glycosyltransferase 
adding the second GalNAc residue and predict 
OgcA is responsible for the addition of the 
terminal Gal. The inability to generate DogcA 
suggests that absence of this gene may be 
deleterious for bacterial cell viability. This 
interpretation is consistent with previous Tn-
Seq analysis showing that insertions are 
unrepresented within the B. cenocepacia ogcA 
(40) and with a report indicating the B. 
pseudomallei K96243 ogcA homologue 
(BPSL2668) is essential for survival (41). It is 
likely that without the terminal Gal the 
incomplete O-linked disaccharide glycan 
cannot be either effectively translocated across 
the membrane or processed by PglL, leading in 
both cases to the accumulation of Und-PP that 
cannot be recycled thus becoming growth 
limiting. Further experiments are required to 
confirm the function of OgcA. 
 Both the O-glycan and the O antigen in B. 
cenocepacia share GalNAc residues (25). 
Therefore, the epimerization of UDP-Glc to 
form UDP-Gal would be needed for O-glycan 
synthesis. Our demonstration that the ogcE 
gene product catalyzes both reactions explains 
why the deletion of this gene results both in 
truncation of O-antigen and loss of protein 
glycosylation. This scenario is similar to that of 
C. jejuni GalE, which contributes to the 
biosynthesis of lipooligosaccharide, capsular 
polysaccharide, and N-linked glycosylation 
(42,43), and N. meningitidis GalE, which plays 
a role in pilin glycosylation and 
lipooligosaccharide synthesis (44). A closer 
homologue of OgcE is the UDP-GalNAc-4-
epimerase of Yersinia enterocolitica, named 
Gne, which was reported to be specific for 
UDP-GalNAc with practically no activity on 
non-acetylated substrates (45). However, we 
provide conclusive biochemical evidence that 
while B. cenocepacia OgcE has a slight 
preference for non-acetylated substrate UDP-
Gal it can also interconvert UDP-GalNAc 
efficiently. 
 We also demonstrate that the general O-
glycosylation pathway is a conserved feature of 
the Burkholderia genus. This conclusion is 
supported by multiple evidence. First, the ogc 
genes are conserved and collinear in most of the 
Burkholderia species for which genomic 
sequencing is available, with only few 
exceptions where some of genes were in 
different genomic locations. Second, analysis 
of the O-glycosylation glycoproteome in a 
subset of B. thailandensis, B. gladioli, and B. 
pseudomallei isolates confirms the production 
of a similar trisaccharide structure in these 
species. Third, B. cenocepacia, B. thailandensis 
and B. gladioli protein lysates reveal 
polypeptides that react with the peanut 
agglutinin, a lectin that recognizes Gal-β(1-3)-
GalNAc terminal disaccharide of the O-glycan 
moiety.   
 The conservation of the glycosylation 
pathway in Burkholderia raises the question of 
the role of protein glycosylation in the biology 
of these bacteria, which despite their ability to 
cause infection in humans and certain domestic 
animals are also widespread in the environment 
(1). We provide evidence that loss of protein 
glycosylation causes global metabolic defects 
in B. cenocepacia concerning the utilization of 
several different carbon sources and tolerance 
to osmotic and oxidative stress. Therefore, 
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general protein O-glycosylation is required for 
metabolic fitness, possibly because it is 
involved in the stability of its protein targets, as 
shown in C. jejuni (46,47). We also found that 
not only are glycosylation defective mutants 
less virulent in the Galleria mellonella 
infection model, but also that the pathogen-host 
interaction at the cellular level is different. 
Indeed, the level of expression of antimicrobial 
peptides is higher and temporally faster in 
larvae infected with the glycosylation defective 
mutants. Delayed expression of antimicrobial 
peptides towards infection with the wildtype 
strain could be due to the rapid replication of 
the bacterium inside the infection model, 
suggesting that B. cenocepacia may need to 
reach certain threshold to cause overwhelming 
induction of G. mellonella immune response, 
which leads to larval death. This can also be 
explained by the higher sensitivity of ∆pglL to 
oxidative stress, which is also induced upon 
Galleria infection. Further, a relation between 
defective transporters and growth in 
invertebrate cells was demonstrated for Listeria 
monocytogenes implying that certain 
nutritional sources are also important substrates 
for bacterial growth in host cells (48). 
Potentially, the ∆pglL defect in utilizing several 
carbon sources suggests that loss of 
glycosylation affects the function of proteins 
involved in nutrient transport across the 
periplasmic space, and could be another reason 
for the reduced virulence in G. mellonella. 
Therefore, loss of the general protein O-
glycosylation system would make 
Burkholderia more susceptible to clearance by 
the host's innate immune, suggesting protein O-
glycosylation could be considered as a novel 
target to develop inhibitors for possible clinical 
applications. 
 Another significant question arising from 
the conservation of the Burkholderia 
glycosylation pathway is whether Burkholderia 
glycoproteins are recognized by the human 
immune system. Burkholderia human 
infections represent a health risk to susceptible 
patient groups such as those with cystic 
fibrosis, as well as patients in endemic areas 
where B. pseudomallei prevails. Being 
multidrug resistant pathogens compounds this 
problem since Burkholderia infections are also 
difficult to treat (49). We show that the vast 
majority of serum samples from cystic fibrosis 
patients infected with B. cenocepacia and B. 
multivorans, as well as from patients with 
melioidosis and glanders have antibodies that 
react with the O-glycosylated DsbA1 protein. 
This suggests that either the Burkholderia 
glycan or the combination of the glycan and the 
target protein at the glycosylation site are 
epitopes specifically recognized by the immune 
system, paving the way to future research to 
determine if these antibodies afford protection 
against infection. 
 In summary, this study has 
comprehensively characterized a conserved 
general protein O-glycosylation pathway in the 
Burkholderia genus demonstrating the 
relevance of protein glycosylation in the 
biology of B. cenocepacia and by extension in 
this group of bacteria widespread in multiple 
environmental niches and also responsible for 
opportunistic infections.   
 
EXPERIMENTAL PROCEDURES 
 Strains and growth conditions. Strains 
and plasmids used in this study are listed in 
Table S3. Bacteria were grown at 37°C in 
Luria-Bertani (LB) medium. Antibiotics were 
used at the following final concentrations: 50 
μg trimethoprim ml-1 for E. coli and 100 μg ml-
1 for B. cenocepacia, 30 μg tetracycline ml-1 for 
E. coli and 100 μg ml-1 for B. cenocepacia and 
40 μg kanamycin ml-1 for E. coli. Ampicillin at 
200 μg ml-1 and polymyxin at 20 µg ml-1 were 
used to select against donor and helper E. coli 
strains in triparental mating. Antibiotics and 
chemicals were purchased from Sigma-Aldrich 
(UK). 
 Recombinant DNA methods and 
deletion mutagenesis. The primers used are 
listed in Table 4. DNA ligations, restriction 
endonuclease digestions, and agarose gel 
electrophoresis were performed according to 
standard techniques (50) or by Gibson 
assembly (51). Restriction enzymes, Antarctic 
phosphatase and T4 DNA ligase were 
purchased from New England Bio labs 
(Ipswich, MA) and used as recommended by 
the manufacturer. E. coli GT115 and DH5α 
cells were transformed by the calcium chloride 
method (50). PCR amplifications were carried 
out using the HotStar HiFidelity polymerase 
(Qiagen). Colony-PCR was performed with 
Taq polymerase (Qiagen). Ampliﬁcations 
reactions were optimized for each primer pair. 
DNA sequencing was performed at the 
sequencing facility in GATC Biotech (London, 
UK). Unmarked, non-polar gene deletion 
mutants were constructed as previously 
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described (52), and verified by DNA 
sequencing of PCR amplicons spanning the 
deletion endpoints.  
 Purification of BCAL2640. A plasmid 
constitutively expressing the BCAL2640 
protein was constructed by amplifying the gene 
with primers Q539 and Q540. The resulting 
amplicon was digested with NdeI and XbaI and 
ligated into a similarly digested pDA12 
resulting in pDA12-BCAL2640, which was 
introduced into K56-2 wild type, ∆pglL, and 
∆ogc by triparental mating (52). Exconjugants 
were isolated by plating on LB agar plates 
supplemented with 100 μg tetracycline ml-1, 
200 μg ampicillin ml-1, 20 μg polymyxin ml-1. 
Cultures of pDA12-BCAL2640 expressed in 
wild type, ∆pglL, or ∆ogc were grown 
overnight at 37◦C. Bacteria were harvested and 
lysed using a cell disrupter (Constant Systems 
Ltd., Northants, UK) at 18 kPsi. Supernatants 
containing soluble BCAL2640 protein were 
incubated with 0.2 M Ni2+-coated sepharose 
beads (GE Healthcare Life Sciences, UK) 
overnight at 4°C with mixing. The beads were 
washed and the His-tagged BCAL2640 was 
eluted twice with 250 mM imidazole. Purified 
BCAL2640 was run on 14% SDS-PAGE and 
stained by PageBlue Protein Staining Solution 
(Thermo Scientific, UK). Gel bands were 
excised and prepared for MS analysis.  
 Purification of DsbA1. Plasmid pMF22 
(pMLBAD-DsbA1) was introduced into wild 
type B. cenocepacia K56-2, ∆pglL, ∆ogc, 
∆ogcX, ∆ogcI, ∆ogcAB, ∆ogcE, and 
∆BCAL3119-3131 by triparental mating (52). 
Exconjugants were selected on LB agar plates 
supplemented with 100 μg trimethoprim ml-1.  
For the purification of the lipoprotein DsbA1, 
stationary phase bacterial cultures were 
harvested at 12000 xg for 15 min at 4°C and 
resuspended in buffer A (1 μg ml−1 DNase I, 
complete EDTA-free protease inhibitor 
cocktail, 2% Triton X-114 in PBS). Bacteria 
were lysed with the cell disrupter, as described 
above. The supernatant was incubated at 37°C 
until phase separation was complete. The 
aqueous phase was removed after 
centrifugation at 10 000 xg for 10 min at 30°C. 
The remaining detergent layer containing the 
glycosylated lipoproteins was diluted to the 
original solution volume with buffer A without 
detergent for 1 h. Ten millimolar imidazole and 
300 mM NaCl were added to the detergent 
phase prior to the addition of an appropriate 
volume of Ni2+ coated sepharose beads 
equilibrated in buffer B (2% Triton X-114, and 
30 mM NaCl in phosphate-buffered saline). 
This solution was allowed to mix overnight at 
4°C. The beads were packed and then washed 
three times with buffer B containing 50 mM 
imidazole. The selected His-tagged DsbA1 was 
eluted twice, with two column volumes, with 
buffer B containing 300 mM imidazole. 
Purified DsbA1 was resolved on 14% SDS-
PAGE and stained by PageBlue protein staining 
dye for MS analysis. Purified DsbA1 was either 
concentrated by TCA 10% precipitation 
overnight or passed on detergent removal spin 
column (ThermoScientific) prior to ELISA and 
NMR analysis respectively.  
 Protein manipulation and 
immunoblotting. Whole-cell lysates were 
prepared from overnight cultures of K56-2 and 
all mutants containing pAMF22 and induced by 
0.2% arabinose overnight at 37◦C in the 
presence of 100 μg trimethoprim ml-1. Two 
hundred μl of cells with O.D600 of 1 were 
pelleted, then resuspended in 1× sample buffer 
with 5% β-mercaptoethanol and boiled for 10 
min. Protein separation was performed by 14% 
SDS-PAGE. His-tagged DsbA1 was revealed 
by immunoblotting using a 1:10,000 dilution of 
the mouse anti-His monoclonal antibody (GE 
Healthcare Life Sciences, UK). Proteins were 
visualized using a Licor Infrared Imaging 
System with Odyssey software. These 
experiments were replicated 3 times. 
 In-gel digestion of proteins. Gel 
separated proteins were processed as 
previously described (53) with minor 
modifications. Briefly, gel bands of interest 
were excised and destained in a 50:50 solution 
of 50 mM NH4HCO3 (pH 8.0) : 100% ethanol 
for 20 min at room temperature with shaking at 
750 rpm. destained samples were then washed 
with 100% ethanol and vacuum-dried to 
dryness. Dried samples were then rehydrated in 
10 mM DTT in 50 mM NH4HCO3 and reduced 
for 60 min at 56°C with shaking. Following 
reduction samples were washed twice in 100% 
ethanol for 10 min to ensure the complete 
removal of DTT and vacuum-dried to dryness. 
Reduced samples were rehydrated in 55 mM 
iodoacetamide in 50 mM NH4HCO3 in the dark 
for 45 min at room temperature. Following 
alkylation samples were washed twice with 
100% ethanol and vacuum-dried. Dried 
alkylated samples were then rehydrated with 
12 ng/µl trypsin (Promega, Madison WI) in 
40 mM NH4HCO3 at 4°C for 1 h. Following 
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rehydration excess trypsin was removed, gel 
pieces covered in 40 mM NH4HCO3 and 
incubated overnight at 37°C. Peptides samples 
were extracted from gel sample twice using 
four gel volumes of 30% ethanol 3% Acetic 
acid followed by four gel volumes of 100% 
ethanol with the supernatant from each 
extraction pooled. The resulting peptide 
mixtures were dried down, desalted using C18 
stage tips (54) and stored on tip at 4°C. Peptides 
were eluted in Buffer B (80% acetonitrile, 0.1% 
Formic acid) and dried down before analysis by 
LC-MS. 
 Generation of whole cell lysates for 
proteome analysis. Burkholderia strains of 
interest were grown overnight on confluent LB 
plates. Plates were flooded with 5 mL of pre-
chilled sterile phosphate-buffered saline (PBS) 
and colonies removed with a cell scraper. Cells 
were washed 3 times in PBS and collected by 
centrifugation at 10,000 x g at 4˚C then snap 
frozen. Frozen whole cell samples were 
resuspended in 4% SDS, 100mM Tris pH 8.0, 
20mM DTT and boiled at 95˚C at 2000rpm for 
10 min. Samples clarified by centrifugation at 
17,000 xg for 10 min, supernatant collected and 
protein concentration determined by 
bicinchoninic acid assay (Thermo Scientific 
Pierce). 200ug of protein from each sample was 
acetone precipitated by mixing 4 volumes of 
ice-cold acetone with one volume of sample. 
Samples were precipitated overnight at -20˚C 
and then spun down at 16,000G for 10 min at 
0˚C. The precipitated protein pellets were 
resuspended with 80% ice-cold acetone and 
precipitated for an additional 4 hours at -20˚C. 
Samples were centrifuged at 17,000 xg for 10 
min at 0˚C, the supernatant was discarded and 
excess acetone driven off at 65 ˚C for 5 min.  
 Digestion of complex protein lysates. 
Dried protein pellets were resuspended in 6 M 
urea, 2 M thiourea, 40 mM NH4HCO3 and 
reduced / alkylated prior to digestion with Lys-
C (1/200 w/w) and trypsin (1/50 w/w) 
overnight (55). Digested samples were 
acidified to a final concentration of 0.5% 
formic acid and desalted with home-made high-
capacity StageTips composed on 5mg 
Empore™ C18 material (3M, Maplewood, 
Minnesota) and 5mg of OLIGO R3 reverse 
phase resin (Thermo Fisher Scientific) 
according to the protocols of Ishihama and 
Rappsilber (56,57). Bound peptides were eluted 
with buffer B, dried and stored at -20 ˚C. 
 Liquid Chromatography and Mass 
Spectrometry analysis. Prior to LC-MS 
analysis, samples were re-suspended in 15 µL 
Buffer A (2% acetonitrile, 0.1% Formic acid). 
LC-MS was performed on either an Agilent 
1290 Series HPLC (Agilent Technologies, 
Mississauga, ON) coupled to LTQ-Orbitrap 
Velos (Thermo Scientific, San Jose CA), a 
Dionex Ultimate 3000 UPLC (Thermo 
Scientific) coupled to an Orbitrap Elite or an 
EASY-nLC1000 system coupled to a Q-
Exactive. For the LTQ-Orbitrap Velos and Q-
Exactive, LC-MS was accomplished using a 
two column system in which samples were 
concentrated prior to separation on a 2-cm-
long, 100-μm-inner diameter fused silica trap 
column containing 5.0-μm Aqua C-18 beads 
(Phenomenex) and then separated using an in-
house packed C18 analytical 75 µm inner 
diameter, 360 μm outer diameter column 
composed of 35 cm ReproSil-Pur C18 AQ 1.9 
μm (Dr. Maisch, Ammerbuch-Entringen, 
Germany) column for the EASY-nLC1000 
system or a 20cm ReproSil-Pur C18 AQ 3.0 µm 
for the Agilent 1290 Series HPLC. Samples 
were concentrated onto the trap for 10 min 
using 100% Buffer A at 5µl/min after which the 
gradient was altered from 100% phase A to 
40% Buffer B over 90 min at 250 nl/min with 
the eluting peptides infused directly into the 
mass spectrometers via nESI. For the Orbitrap 
Elite LC-MS was accomplished using a two-
column chromatography set up comprising a 
PepMap100 C18 20 mm x 75 μm trap and a 
PepMap C18 500 mm x 75 μm analytical 
column (Thermo Scientific). Samples were 
concentrated onto the trap column at 5 μl/min 
for 5 mins and infused into an Orbitrap Elite at 
300 nl/min via the analytical column. One 
hundred and 80-min gradients were run altering 
the buffer composition from 1% buffer B to 
28% B over 145 mins, then from 28% B to 40% 
B over 10 mins, then from 40% B to 100% B 
over 2 mins, the composition was held at 100% 
B for 3 mins, and then dropped to 3% B over 5 
mins and held at 3% B for another 15 mins. All 
instruments were operated in a data-dependent 
manner using Xcalibur v2.2 (Thermo 
Scientific). For samples analyzed on the LTQ-
Velos, one full precursor scan in the Orbitrap 
(resolution 60,000; 500-2,000 Th, AGC target 
of 1 × 106) was followed by the selection of the 
top four most intense, multiply charged ions 
above 5000 counts for collision-induced 
dissociation (CID, normalized collision energy 
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35, AGC of 4 × 104) followed by higher energy 
collisional activated dissociation (HCD, 
resolution 7500, normalized collision energy 
40, ACG of 2 x 105) with 30 s dynamic 
exclusion enabled as previously described (55). 
For samples analyzed on the Orbitrap Elite, one 
full precursor scan in the Orbitrap (resolution 
60,000; 500-2,000 Th, AGC target of 1 × 106) 
was followed by the selection of the five four 
most intense, multiply charged ions above 
10000 counts for collision-induced dissociation 
(CID, normalized collision energy 35, AGC of 
4 × 104) followed by higher energy collisional 
activated dissociation (HCD, resolution 15000, 
normalized collision energy 40, ACG of 2 x 
105) with 45 s dynamic exclusion enabled. For 
samples analyzed on the Q-Exactive, one full 
precursor scan (resolution 70,000; 350-2,000 
m/z, AGC target of 3 × 106) was followed by 10 
data-dependent HCD MS-MS events 
(resolution 35k, normalized collision energy of 
25 with 50% stepping, AGC target of 1 × 106) 
with 25 s dynamic exclusion enabled. Area of 
the most intense charge state of each species 
was used to assess the relative levels / 
distribution of observed peptides.  
 Glycopeptide identification. Raw data 
files were processed with Proteome Discover 
version 1.4 (Thermo Scientific) to generate mgf 
files. The resulting mgf files were searched 
using MASCOT v2.4 (Matrix Science, 
provided by the BC Proteomics Network 
http://www.proteincentre.com/mascot/). 
Searches were carried out using semi-trypsin 
specificity, carbamidomethylation of cysteine 
as a fixed modification and Oxidation (M) as a 
variable modification. A precursor and product 
tolerance of 20ppm was used and B. 
cenocepacia data searched against the B. 
cenocepacia K56-2Valvano proteome 
(http://www.uniprot.org/taxonomy/985076, 
downloaded from NCBI February 15th 2013), 
while non-B. cenocepacia species were 
searched against the NCBI proteome database 
(Downloaded 1st of September 2016) with the 
taxonomy restricted to “Other Proteobacteria”. 
Scan events that did not result in peptide 
identification were manually inspected and 
identified as possible glycopeptides based on 
the presence of the diagnostic oxonium ion 
204.09 m/z of HexNAc or 188.09 m/z in the 
case of QuiNAc modified peptides. To 
facilitate glycopeptide assignments from HCD 
scans, the ions below the mass of the predicted 
deglycosylated peptides were extracted with 
Xcalibur v2.2 using the Spectrum list function. 
Ions with a deconvoluted mass above that of the 
deglycosylated peptide and ions corresponding 
to known carbohydrate oxoniums were 
removed in a similar approach to post-spectral 
processing of ETD data (58) and searched as 
above with mascot. All spectra were searched 
with the decoy option enabled with all peptides 
passing a 1% FDR. Identified glycopeptide 
spectra were manually inspected and spectra 
annotated according to the nomenclature of 
Roepstorff and Fohlman (59) (Supplementary 
Data S1-S4). Glycopeptides derived from 
clinical Burkholderia strains were matched to 
either the B. gladioli reference strain BSR3 or 
the B. pseudomallei reference strain K96243. 
 Structural characterization of the 
protein glycan moiety. DsbA1, that was 
heterologously expressed in B. cenocepacia, 
obtained from TCA precipitation was dissolved 
in water (1 ml), and two aliquots of Proteinase 
K (0.3 mg each, Sigma P-2308) were added at 
37°C, at 8 h interval, with last addition left 
overnight. The solution was directly loaded on 
a column packed with Bio-Gel P10 (d = 1.5 cm, 
h = 118 cm) using water as eluent (flow = 16 
ml/h) and monitoring the eluate with a 
refractive index detector (Knauer K-2301). 
Fractions were pooled and monitored by 1H 
NMR and the fraction enriched in the 
glycopeptide was eluted after approx. 40% of 
the total column volume. NMR analyses were 
performed on a Bruker 600 MHz equipped with 
a cryo-probe. Spectra were recorded at 15°C 
using acetone as internal standard (1H 2.225 
ppm, 13C 31.45 ppm). 2D spectra (DQF-
COSY, TOCSY, TROESY, and gHSQC) were 
recorded using Bruker software (TopSpin 2.1). 
Homonuclear experiments were recorded using 
512 FIDs of 2048 complex with 40 scans per 
FID, for TOCSY and TROESY spectra a 
mixing time of 100 and 300 ms was applied, 
respectively. HSQC spectrum was acquired 
with 512 FIDs of 2048 complex point and 60 
scans per FID; spectra were processed and 
analyzed using Bruker TopSpin 3 program. 
 Extraction and analysis of B. 
cenocepacia lipopolysaccharide. Proteinase 
K-treated whole cell lysates were resolved by 
SDS-PAGE (16% v/v polyacrylamide) and 
visualized following silver staining (60). 
Complementation of O-antigen synthesis in 
∆ogc was done by conjugating pXO23 
(pAP20::ogcE) into the mutant by triparental 
mating and exconjugants were counterselected 
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on 100 μg chloramphenicol ml-1, 200 μg 
ampicillin ml-1 and 20 μg polymyxin ml-1. 
 OgcE enzymatic assay. BCAL3117 was 
amplified by primers Q729 and Q728, cut by 
restriction enzymes NdeI and EcoRI and cloned 
in pET28 vector containing an N-terminal 6x 
His-tag that had been cut with the same 
restriction enzymes. Expression was induced 
by IPTG 0.5 mM for 3 h at 37°C for a 300 ml 
culture. The cells were harvested by 
centrifugation and lysed by passage in a cell 
disruptor after resuspension in buffer A: 50 mM 
Tris-HCl, 100 mM NaCl. OgcE was purified 
using a 3 ml Fast Flow chelating Sepharose 
column loaded with Ni2+ and equilibrated in 
buffer A. After extensive washing with buffer 
A, OgcE was eluted with increasing 
concentrations of imidazole (100-400 mM). 
The purified enzyme was preserved by addition 
of glycerol (25% final concentration) and 
frozen at -20oC. Reactions were set on 4 
substrates: UDP-Gal, UDP-Glc, UDP-GalNAc 
and UDP-GlcNAc each with NADP+ or NAD+. 
Reactions were done in Tris 200 mM pH 8, with 
0.1 mM substrate and 0.1 mM cofactor in a 
volume of 10 μl, with 7.3 μl enzyme fraction 
(comprising ~ 5 μg of enzyme) and incubated 
for 4h at 37oC unless stated otherwise in the 
legends to the figures. The reactions were 
analyzed by capillary electrophoresis (PACE 
MDQ, Beckman) using a bare silica capillary, 
200 mM Borax buffer pH 9 and UV detection 
at 254 nm (61). The % of conversion was 
obtained by integrating the substrate and 
product peak surface areas using the 32Karat 
software. 
 Oxidative and osmolar susceptibility 
testing. Sensitivity towards different 
concentrations of hydrogen peroxide (Sigma) 
was assessed using the bioscreen. Bacterial 
cultures were diluted to an OD600 of 0.01 in LB 
and dispensed in 100-well plates in 270 µl 
volumes. 30 ml aliquots of hydrogen peroxide 
in different concentrations were added to the 
bacterial cultures. Plates were incubated in a 
Bioscreen C automated growth curve reader for 
16 h with OD600 readings taken every 1 h. The 
same procedure was employed to determine the 
susceptibility towards high concentrations of 
NaCl using glucose as a carbon source. 
 Survival assay was also made after 
challenging bacterial cultures in LB with 
hydrogen peroxide at concentrations of either 
300 μM with bacterial inoculum of 8x106 
cfu/ml or 1 mM with bacterial inoculum of 
8x107 for 1 h at 37ºC with shaking. Samples 
were withdrawn and serially diluted in PBS. 
Then, 10 μl portions were dropped onto the 
surface of LB agar plates. The plates were 
incubated at 37ºC for 24 h, the resulting 
colonies were counted and the % of survival 
was determined relative to parallel-untreated 
control samples. 
 Phenotypic microarray experiments. 
The metabolic phenome of B. cenocepacia 
K56-2 and ∆pglL was assessed using pre-
configure Biolog Phenotype MicroArrays 
(PMs) from Biolog Inc., Hayward, CA, USA. 
We used PM plates 1 and 2, which contain 190 
of the most common carbon sources in 96-well 
arrangements composed of one negative 
control well and 95 wells prefilled with a given 
carbon source in a dried state. PM experiments 
were performed following the standard 
protocol (62). Briefly, B. cenocepacia strains 
were grown on LB agar plates for 36 h at 37ºC. 
A cell suspension of 95 % transmittance in 
Biolog solution IF-0 was prepared by 
resuspending bacteria grown on LB agar plates. 
Dye A was then added and then 100 μl/well 
were transferred to each of the 96-well PM 
microplates (a set of 95 substrates and one 
blank well). The plates were incubated at 37 °C 
for 48 h. The optical density (OD600) values 
were then measured using microtiter plate 
reader. Each experiment was performed as 
biological duplicates and growth differences 
were established by comparing the area under 
the growth curve (AUC). Growth in a given 
carbon source was considered positive when 
median AUC was more than 40% higher than 
negative control AUC. A cut-off value of 80% 
was used to determine a significant growth 
reduction of the mutant compared to wildtype. 
Hits ranged from reduction in growth from 80% 
up to less than 60% (Fig. 8A). Positive results 
were subsequently validated by the performing 
growth studies using the automated Bioscreen 
C in M9 minimal media to test the utilization of 
selected carbon sources compared to PM1 and 
PM2 plates. Bacterial cultures were diluted to 
approximately an OD600 of 0.01 in M9 minimal 
media deprived of carbon sources and 
dispensed in 100-well plates in 270 µl volumes. 
Each required carbon source was tested 
individually by adding 30 µl of a stock solution 
to each to the 100-well Bioscreen plate to give 
final concentrations of 0.2% (W/V) in the 
wells. Plates were incubated in a Bioscreen C 
automated growth curve analyser for 48 h and 
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bacterial growth was assessed turbidimetrically 
at 600 nm every 2 h. Comparisons were also 
made by determining the AUC obtained over 4 
biological replicas in triplicate. 
 Proteolytic activity. To determine 
protease activity, overnight cultures grown in 
LB were diluted to an OD600 of 1, and 3 μl of 
this culture was spotted onto a nutrient agar 
plate containing 1.5% skim milk (63). The 
plates were incubated for 48 h at 37°C, after 
which the radii of the cleared zones 
surrounding the colonies were measured. 
 Galleria mellonella larvae Infection. G. 
mellonella wax moth larvae were acquired from 
UK Waxworms Ltd. and stored in wood 
shavings in the dark at 16 °C prior to infection. 
Larvae of approximate weight of 250 to 350 mg 
were used. Bacteria were grown in 5 ml LB, 
harvested during exponential phase, 
resuspended in sterile PBS and serially diluted. 
The surface of the larvae was disinfected by 
ethanol (70%) and then larvae were injected 
with 10 μl of bacterial suspension, containing 
approximately 8x104 CFU/ml of either K56-2 
or the tested mutants, into the last right proleg 
by use of a Hamilton syringe with a 26-gauge 
needle. A group of 10 control larvae were 
injected with 10 μl of PBS in parallel. Larvae 
were kept at 37°C in the dark. Larval survival 
was monitored at 24 h intervals over a period of 
72 h and was judged based on visual 
appearance and lack of movement in response 
to stimuli. Three independent experiments were 
performed.  
 Determination of in vivo bacterial loads 
in G. mellonella. Larvae were infected with 
approximately 8 x 104 CFU of K56-2 or ∆pglL 
or ∆ogc. Groups of three insects were collected 
at 24 h and 48 h, and hemolymph samples from 
3 larvae (approximately 100 μl) were collected 
in microcentrifuge tubes containing 10 μl of a 
saturated solution of N-phenylthiourea (Sigma-
Aldrich, UK). Serial dilutions of the 
homogenate in PBS were plated on LB agar 
supplemented with spectinomycin 100 μg ml-1, 
and colonies were counted after incubation at 
37°C for 24 h. Three independent experiments 
were performed. No CFU were recovered from 
non-infected larvae in LB agar supplemented 
with spectinomycin.  
 RNA extraction and RT-PCR. Larvae 
were infected with approximately 1 x 104 CFU 
of exponentially growing bacterial cultures. At 
8 h and 18 h post infection, 3 larvae from either 
the control PBS group or the infected group 
were homogenized on ice with 1ml of Tri-
reagent (Ambion), using Stuart homogenizer 
SHM2 (Bibby Scientific Limited, 
Staffordshire, UK). Total RNA was puriﬁed by 
a standard chloroform-isopropyl alcohol 
protocol, and the obtained RNA was further 
puriﬁed using a Nucleospin RNAII kit 
(Macherey-Nagel) that included one step of on-
column DNAse treatment, following the 
manufacturer’s instructions. The quantification 
of purified RNA samples was performed with a 
nanodrop (Nanovue Plus, GE Healthcare). 
cDNA was obtained from 1 μg total RNA by 
using a commercial Moloney murine leukaemia 
virus (M-MLV) reverse transcriptase 
(Invitrogen, UK). Real-time PCR (RT-PCR) 
analyses were performed with a Mx3005p 
qPCR system (Agilent Technologies, UK). One 
hundred nanograms of cDNA were used as the 
template in a 20-μl reaction mixture containing 
KapaSYBR Fast qPCR mix (Kapa Biosystems) 
and primer mix. Actin and 18S rRNA genes 
were ampliﬁed as housekeeping genes. The 
primers used are listed in Table S1. The 
thermocycling protocol was as follows: 95°C 
for 3 min for hot-start polymerase activation, 
followed by 45 cycles of denaturation at 95°C 
for 15 s and annealing at 60°C for 30 s. SYBR 
green dye ﬂuorescence was measured at 521 
nm during the annealing phase. Fold changes in 
gene expression were calculated using the 
Livak method (∆∆CT) (64) with normalization 
to the actin gene (Supplementary Data S6).  
 ELISA. Antibodies against glycosylated 
and unglycosylated DsbA1 were detected by 
indirect ELISA. Ninety-six well Nunc 
MaxiSorp plates were coated with 50 μl of 
purified DsbA1 protein expressed in K56-2 WT 
(glycosylated) or in ∆pglL (non-glycosylated) 
and diluted in coating buffer 
(carbonate/bicarbonate, 100 mM, pH 9.6) to 
reach a final concentration of 2-4 μg/ml. 
Control wells contained only coating buffer. 
The plates were covered by plastic adhesive 
film and incubated at 4°C overnight. Coating 
solution was removed and plates were washed 
with 300 μl PBS/Tween20 (0.05%). Additional 
blocking was achieved by adding 300 μl of 
blocking buffer (BSA 5%). Plates were covered 
and incubated at room temperature for 1 h and 
then washed 3 times with PBS/Tween20. Fifty 
microliters of serum samples, diluted in half-
strength blocking buffer, were added to the 
wells and incubated for 90 min at room 
temperature. Normal human serum from non-
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infected individuals was used as a negative 
control. Plates were washed 4 times with 
PBS/Tween20. Fifty microliters of biotinylated 
rabbit anti-human IgG secondary antibody 
diluted to 1:20000 (1 μl in 20 ml PBS) were 
added and incubated for 1 h at room 
temperature. Plates were washed 5 times with 
PBS/Tween20. Fifty microliters of 
Streptavidin-Horseradish Peroxidase diluted 
1:300 in PBS were then added to the wells and 
incubated for 1 h in dark at room temperature. 
After washing 4 times with PBS/Tween20, 50 
μl of the substrate solution 3,3',5,5'-
tetramethylbenzidine were added per well and 
incubated in the dark at room temperature. 
After sufficient color development, 30 μl of 
stop solution (3M HCl) were added and the 
absorbance of each well was read with 
POLARstar Omega microplate reader (BMG 
LABTECH, Ortenberg, Germany) at 450nm. 
Three independent repeats were made for every 
sample, each done in duplicate. A positive 
ELISA test was defined by an absorbance 
reading exceeding the cut-off value computed 
by two standard deviations above the mean of 
the negative control. We also performed a 
confirmatory reverse ELISA was done, in 
which the glycan specific antibodies from 
positive serum samples were adsorbed using 
the glycosylated DsbA1 protein by incubating 
the samples with the glycosylated protein at a 
concentration of 100 µg/ml for 2 h at room 
temperature and overnight at 4°C for 3 
successive passages. Serum samples were then 
collected and used in a normal ELISA 
procedure as described above in parallel to the 
same samples without adsorption. Results are 
presented in ELISA units in which a cut-off of 
2X standard deviation of the mean of the 
negative control was used to decide whether a 
serum sample is reactive towards the glycan or 
not. 
 Ethics. Patients with confirmed diagnosis 
of CF were recruited between 2010-2014 
during routine outpatient appointments at the 
adult CF Centre in the Belfast Health and Social 
Care Trust (Belfast City Hospital) and provided 
written informed consent for the provision of 
serum samples. The study was approved by the 
Office for Research Ethics Committees 
Northern Ireland (10/NIR01/41) and co-
sponsored by the Belfast Health and Social 
Care Trust and Queen’s University Belfast 
(10067SE-OPMS).  Samples from patients 
attending the Manchester Adult CF Clinic were 
collected under the framework of the 
Manchester Respiratory and Allergy Biobank 
(ManRAB) (Full ethical approval was provided 
by the ManRAB ethics committee; REC 
reference: 10/H1010/7). Blood samples were 
collected from adult patients with melioidosis 
who had received written information before 
signing the consent form, approved by the 
Khon Kaen University Ethics Committee for 
Human Research Number HE561234. The 
convalescent human glanders serum was 
obtained under USAMRIID protocol FY00-15. 
The investigators adhered to the policies 
regarding the protection of human subjects as 
prescribed by 45 CFR 46 and 32 CFR 219 
(Protection of Human Subjects). Opinions, 
interpretations, conclusions and 
recommendations are those of the authors and 
are not necessarily endorsed by the U.S. Army 
or any of the granting agencies that supported 
this study. 
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Figure Legends 
 
FIGURE 1. Identification of the O-glycosylation cluster (ogc) in B. cenocepacia. A, genetic 
organization of the ogc cluster (BCAL3114-BCAL3118), placed between the O-antigen and lipid A-
core clusters. Names of ORFs indicated above the arrows are according to the original gene annotation 
(25). Names below are the ones assigned in the current study. B, proposed model for the general O-
glycosylation assembly pathway in B. cenocepacia; OgcI: initiating enzyme, OgcE: UDP-
glucose/galactose epimerase, OgcAB: glycosyltransferases, OgcX: flippase, and PglL: 
oligosaccharyltransferase. C, synteny of ogc genes in members of the Burkholderia genus. Genes 
indicated in bold are the ones used to search for synteny in the SyntTax server. The species showing 
similar arrangements are listed for each group.  The synteny scores ranged from 55 to 96 (>30 is 
considered highly significant conservation) (26). D, relative gel mobility of BCAL2640 and DsbA1 
polypeptides in ∆ogcX-ogcI and single deletion mutants. Similar results were obtained in 3 biological 
repeats. Left panel: Coomassie-stained 14% SDS-polyacrylamide gel of the purified B. cenocepacia 
BCAL2640 protein expressed in wildtype K56-2, ∆pglL, and ∆ogc. Right panel Western blot of His-
tagged DsbA1 acceptor protein expressed in the parental K56-2 strains and the mutants ∆pglL, ∆ogcX, 
∆ogcX, ∆ogcI, ∆ogcAB, ∆ogcE and ∆O-antigen cluster (∆BCAL3119-BCAL3131). 
 
FIGURE 2. Identification of PglL and Ogc dependent glycosylation of BCAL2640. A-C, MS-MS 
analysis of detected glycopeptide, CID fragmentations confirms that the peptide is modified with at 
least two glycans corresponding to A, HexNAc-HexNAc-262 (m/z 959.97, +4 corresponding to 
3835.868 Da) and B, HexNAc-HexNAc-Hex (m/z 934.97, +4 corresponding to 3735.859 Da). C, HCD 
fragmentation of the HexNAc-HexNAc-Hex modified peptide confirming the identity of the peptide 
sequence. D-F, extracted ion chromatograms of the major charge state, +3, of the glycosylated 
(modified with HexNAc-HexNAc-Hex) and non-glycosylated forms of 
152YAPPPAAVPVAATSGAQGGAAAAAAPAGTKPANAPR187. In K56-2 (wildtype), the 
BCAL2640 glycosylated peptide was >15-fold more abundant than the unglycosylated form. This 
peptide was not glycosylated in ΔpglL or ΔogcX-ogcI. *denotes deglycosylated peptide resulting from 
in-source fragmentation. 
 
FIGURE 3. NMR spectra of the glycopeptide. Representative regions of the NMR spectrum acquired 
at 600 MHz spectrometer, in D2O at 15°C, for the glycopeptides from DsbA1 after Proteinase K 
digestion and chromatographic purification. A, zoom of 1H NMR spectrum in the ring proton region, B, 
multiplicity edited 1H-13C HSQC spectrum with signals in grey represent methylene carbon atoms; the 
inset shows a zoom of the downfield region with the three anomeric resonances of A-C residues. C, 
superimposition of 1H-1H TOCSY (grey) and 1H-1H T-ROESY (black) spectra. Attribution of most 
relevant cross peaks is indicated nearby the corresponding density, and labels reflect those reported in 
Table S1. The structure of the glycopeptide’s glycan moiety, along with the labels used during spectra 
attribution, is shown as well panel B. Unattributed peaks are related to peptides signals. 
 
FIGURE 4.  Comparison of effects of single ogc mutants on LPS synthesis and protein 
glycosylation. Similar results were obtained in 3 biological repeats. A, proteinase K-treated whole cell 
lysates were resolved on 14% tricine gel and silver staining. Arrowheads indicate a lipid A-core band 
+ truncated O antigen (see Results). B, western blot of His-tagged DsbA1 acceptor protein expressed 
in K56-2 WT, ∆pglL and ∆ogc + (OgcE). 
 
FIGURE 5. OgcE enzymatic activity as UDP-glucose and UDP-GlcNAc epimerase. Capillary 
electrophoresis electrophoregrams showing the C4 epimerase activity of OgcE on (A) UDP-Glc, (B) 
UDP-GlcNAc, UDP-Gal (C), and UDP-GalNAc (D) and in the presence of NAD+ (A and C) or NADP+ 
(B and D).  + and - signs indicate presence or absence of OgcE in the reaction. Reactions were analyzed 
at equilibrium after 4 h incubation at 37oC in the presence of 0.1 mM substrate, 0.1 mM cofactor and 5 
µg enzyme in a total volume of 10 µl of Tris-HCl 200 mM pH8. Two sets of samples prepared with 
independent OgcE enzyme fractions and each including one reaction per condition were analyzed with 
2 CE runs per sample. Both sets showed similar data at equilibrium and only 1 set is shown in the figure. 
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Activity assessment and peak assignments were also based on optimization at different enzyme / 
substrate ratios and various reaction times, and based on co-injections with standards.  
 
FIGURE 6. Effect of O-glycan biosynthesis gene disruptions on protein glycosylation. A, DsbA1 
derived glycopeptide 23VQTSVPADSAPAASAAAAPAGLVEGQNYTVLANPIPQQQAGK64 
indicating the sites of HCD fragmentation. B, the four glycoforms observed corresponded to Glycan A 
(HexNAc-HexNAc-Hex, m/z 1543.10, +3, 4626.266Da), Glycan B (HexNAc-HexNAc-262, m/z 
1576.44, +3 ), QuiNAc-Rha (m/z 1464.75, +3, 4391.226Da), and a single HexNAc (m/z 1421.39, +3, 
4261.146Da). C, semi-quantitative comparison of each glycoform in different genetic backgrounds 
using the area under the curve of the extracted ion chromatograms for all observed glycoforms of the 
DsbA1 peptide. 
 
FIGURE 7. Glycopeptides detected in B. thailandensis, B. gladioli, and B. pseudomallei are 
modified by an identical trisaccharide to that in B. cenocepacia. CID fragmentation (left panels) 
enabled the identification of the expected HexNAc-HexNAc-Hex glycan attached to peptides, while 
HCD fragmentation (right panels) confirmed the identity of the peptide sequences corresponding to the 
B. thailandensis ABC transporter, periplasmic substrate-binding protein (BTH_I3002, m/z 1007.466, 
+2, 2012.9161 Da), the B. gladioli Bifunctional uroporphyrinogen-III synthetase/uroporphyrin-III C-
methyltransferase (bgla_1g31160, m/z 763.359, +3, 2779.3218 Da), and the B. pseudomallei serine 
protease inhibitor Ecotin (m/z 927.449, +3, 2779.3218 Da). 
 
FIGURE 8. Metabolic alterations in the protein O-glycosylation mutant ∆pglL. A, heat map for 
carbon source phenotypes as determined by phenotypic microarrays using an Omnilog system (see 
Materials and Methods). Yellow represents wildtype growth. Blue shading denotes ranges of growth 
below 80% of the wildtype growth in the same carbon source, calculated by comparing the area under 
curve of wildtype and mutant strain (AUC). The complete results for all carbon sources tested are 
presented in Supplementary Data S5. B, selective carbon sources giving differences between K56-2 and 
∆pglL were independently validated by generating growth curves measured by the automated bioscreen 
C using M9 minimal medium with the relevant carbon source under investigation. Statistical differences 
(mean ± standard deviation) of the area under each growth curve were analyzed by multiple t-test 
comparisons with confidence interval of 95%. n=4 per carbon source. *, p = 0.02; **, p < 0.01; ***, p 
< 0.001. C, casein proteolytic activity of K56-2, ∆pglL, and the complemented mutant (∆pglL + PglL) 
was assayed casein-containing nutrient agar plates. Plates shown are representatives of at least 2 
experiments done in triplicates. D, quantification of the data in C by measuring the clear halo around 
the colonies after incubation at 37°C for 48 h. Values are expressed as mean ± standard deviation in 
millimetres. Statistical differences were analyzed by one-way ANOVA with Tukey's multiple 
comparisons tests; α = 0.01; ***, p < 0.0001. 
 
FIGURE 9. Role of O-glycosylation in bacterial proliferation and G. mellonella larval mortality. 
A, larvae were injected with 8x104 CFU of parental and mutant strains and the percent survival was 
monitored over 72 h postinfection. Statistical differences (means ± standard deviations) were examined 
by 2-way ANOVA with Tukey's multiple comparisons tests; a=0.05. B, hemolymph from B. 
cenocepacia-infected larvae (n=3) was pooled and CFU were determined by viable count. Results are 
presented as a superimposed scatter plot and statistical differences (means ± standard deviations) were 
examined by 2-way ANOVA as indicated above. C, transcriptional activation of immune-responsive 
genes following infection determined by quantitative real-time RT-PCR analysis. The graphs show the 
normalized fold expression levels of the target transcripts relative to those in PBS-injected animals, and 
represent means ± standard deviations of 3 independent experiments, each with two technical replicas. 
Expression data were normalized to the expression of the housekeeping actin gene. PGRP, 
Peptidoglycan recognition protein; IMPI, inducible metallo-protease inhibitor. Data were statistically 
analyzed by two-way ANOVA with Tukey's multiple comparisons tests and a=0.05. ns, non-
significant. The calculated p values from individual comparisons are indicated in the figure. 
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FIGURE 10.  Immune reaction of Burkholderia O-glycan towards convalescent sera from 
Burkholderia infected patients. A, Indirect ELISA results using as an antigen purified glycosylated 
DsbA1 protein produced in B. cenocepacia K56-2 and serum samples collected from patients infected 
with B. cenocepacia, B. multivorans, B. mallei, and B. pseudomallei. Non-glycosylated heterologously-
expressed DsbA1 protein in ∆pglL was used in the experiment. Thin arrows point at the serum samples 
that reacted with both glycosylated and unglycosylated DsbA1 heterologously expressed in K56-2 and 
∆pglL, respectively. Three independent experiments were done, each in duplicate. Thick arrows point 
at the serum samples that gave negative results with glycosylated DsbA1. B, serum samples were 
adsorbed by incubation with the glycosylated DsbA1 protein for 3 successive passages prior to ELISA. 
Two independent experiments were done. Dotted blue lines in A and B indicate the negative cut-off 
OD450 value for background color in the ELISA determined by running ELISA assays in normal human 
serum from 30 donors. Error bars represent standard deviation of the mean. 
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